問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2213Cases

2018-11-01 - 2021-03-30

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
6Sites

Recruiting2Sites

Terminated2Sites

周仁偉
China Medical University Hospital-Taipei

未分科

林春吉
Taipei Veterans General Hospital

Division of Colorectal Surgery

2024-04-01 - 2027-03-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2019-06-01 - 2022-12-31

Phase II

A Pilot Study of Oraxol in Subjects With Cutaneous Angiosarcoma

  • Condition/Disease

    Cutaneous Angiosarcoma

  • Test Drug

    Oraxol

Participate Sites
2Sites

Recruiting2Sites

2020-12-01 - 2022-06-24

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2013-05-20 - 2018-12-31

Phase III

A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease.

  • Condition/Disease

    mild to moderate Alzheimer’s disease

  • Test Drug

    masitinib

Participate Sites
6Sites

Terminated6Sites

2014-02-19 - 2017-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2006-03-01 - 2010-03-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Study ended6Sites

2009-09-01 - 2013-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2014-09-01 - 2016-02-29

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2019-03-01 - 2020-06-30

Phase II

A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3

  • Condition/Disease

    Solid Tumors

  • Test Drug

    Debio 1347

Participate Sites
7Sites

Terminated7Sites

1 138 139 140 141 142 222
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB